Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.

Phase 3

Terminated

Conditions: Atherosclerosis
Acute Coronary Syndrome (ACS)

Interventions: Drug: Cangrelor
Drug: Placebo bolus & placebo infusion
Drug: clopidogrel
Drug: Placebo capsules - end of PCI
Drug: Placebo capsules - end of infusion

First Posted Date: 2006-10-06

Last Posted Date: 2014-05-05

Lead Sponsor: The Medicines Company

Target Recruit Count: 5364

Registration Number: NCT00385138

Locations: 🇺🇸
Innovis Health, Fargo, North Dakota, United States

ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"

Phase 2

Completed

Conditions: Ischemia

First Posted Date: 2006-08-04

Last Posted Date: 2010-08-31

Lead Sponsor: Sanofi

Target Recruit Count: 110

Registration Number: NCT00360386

Trial in Subjects Undergoing Cardiac Catheterization With Planned Percutaneous Coronary Intervention With Stenting

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Prasugrel
Drug: Clopidogrel
Drug: Placebo for Prasugrel
Drug: Placebo for Clopidogrel

First Posted Date: 2006-07-28

Last Posted Date: 2010-08-31

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 201

Registration Number: NCT00357968

Locations: 🇮🇱
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tel Hashomer, Israel

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

Phase 2

Completed

Conditions: Coronary Arteriosclerosis
Acute Coronary Syndrome

Interventions: Drug: prasugrel 10 mg
Drug: clopidogrel
Drug: prasugrel placebo
Drug: prasugrel 60 mg
Drug: clopidogrel placebo

First Posted Date: 2006-07-25

Last Posted Date: 2010-11-03

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 139

Registration Number: NCT00356135

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Houston, Texas, United States

Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial

Phase 4

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2006-06-23

Last Posted Date: 2008-08-21

Lead Sponsor: Intermountain Health Care, Inc.

Target Recruit Count: 100

Registration Number: NCT00343876

Locations: 🇺🇸
LDS Hospital, Salt Lake City, Utah, United States

Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS

Phase 3

Completed

Conditions: Angina Unstable
Acute Coronary Disease

Interventions: Drug: Clopidogrel
Drug: acetylsalicyclic acid (ASA)

First Posted Date: 2006-06-09

Last Posted Date: 2010-11-18

Lead Sponsor: Sanofi

Target Recruit Count: 25086

Registration Number: NCT00335452

Locations: 🇬🇧
Sanofi-Aventis Administrative Office, Guildford, Surrey, United Kingdom
🇦🇺
sanofi-aventis Australia & New Zealand administrative office, Macquarie Park, Australia
🇪🇸
Sanofi-Aventis Admnistrative Office, Madrid, Spain